BSHI/BTS guidance on crossmatching before deceased donor kidney transplantation
dc.contributor.author | Dunn, Paul | |
dc.date.accessioned | 2022-01-19T11:28:05Z | |
dc.date.available | 2022-01-19T11:28:05Z | |
dc.date.issued | 2021-09-23 | |
dc.identifier.citation | Peacock, S., Briggs, D., Barnardo, M., Battle, R., Brookes, P., Callaghan, C., Clark, B., Collins, C., Day, S., Diaz Burlinson, N., Dunn, P., Fernando, R., Fuggle, S., Harmer, A., Kallon, D., Keegan, D., Key, T., Lawson, E., Lloyd, S., Martin, J., … Worthington, J. (2022). BSHI/BTS guidance on crossmatching before deceased donor kidney transplantation. International journal of immunogenetics, 49(1), 22–29. https://doi.org/10.1111/iji.12558 | en_US |
dc.identifier.other | 10.1111/iji.12558 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12904/15086 | |
dc.description.abstract | All UK H&I laboratories and transplant units operate under a single national kidney offering policy, but there have been variations in approach regarding when to undertake the pre-transplant crossmatch test. In order to minimize cold ischaemia times for deceased donor kidney transplantation we sought to find ways to be able to report a crossmatch result as early as possible in the donation process. A panel of experts in transplant surgery, nephrology, specialist nursing in organ donation and H&I (all relevant UK laboratories represented) assessed evidence and opinion concerning five factors that relate to the effectiveness of the crossmatch process, as follows: when the result should be ready for reporting; what level of donor HLA typing is needed; crossmatch sample type and availability; fairness and equity; risks and patient safety. Guidelines aimed at improving practice based on these issues are presented, and we expect that following these will allow H&I laboratories to contribute to reducing CIT in deceased donor kidney transplantation. | |
dc.description.uri | https://onlinelibrary.wiley.com/doi/10.1111/iji.12558 | en_US |
dc.language.iso | en | en_US |
dc.subject | HLA | en_US |
dc.subject | antibodies | en_US |
dc.subject | kidney transplantation | en_US |
dc.subject | virtual crossmatching | en_US |
dc.title | BSHI/BTS guidance on crossmatching before deceased donor kidney transplantation | en_US |
dc.type | Article | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | https://doi.org/10.1111/iji.12558 | en_US |
rioxxterms.type | Journal Article/Review | en_US |
refterms.dateFCD | 2022-01-19T11:28:05Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2022-01-19T11:28:05Z | |
refterms.panel | Unspecified | en_US |
refterms.dateFirstOnline | 2022-02 | |
html.description.abstract | All UK H&I laboratories and transplant units operate under a single national kidney offering policy, but there have been variations in approach regarding when to undertake the pre-transplant crossmatch test. In order to minimize cold ischaemia times for deceased donor kidney transplantation we sought to find ways to be able to report a crossmatch result as early as possible in the donation process. A panel of experts in transplant surgery, nephrology, specialist nursing in organ donation and H&I (all relevant UK laboratories represented) assessed evidence and opinion concerning five factors that relate to the effectiveness of the crossmatch process, as follows: when the result should be ready for reporting; what level of donor HLA typing is needed; crossmatch sample type and availability; fairness and equity; risks and patient safety. Guidelines aimed at improving practice based on these issues are presented, and we expect that following these will allow H&I laboratories to contribute to reducing CIT in deceased donor kidney transplantation. | en_US |
rioxxterms.funder.project | 94a427429a5bcfef7dd04c33360d80cd | en_US |